Latent Lines

LEU — LEU

5.89% of the book · -12.01% since entry · entered 2026-05

Sits on

One-line thesis

The only US-licensed HALEU producer sits at the mandatory processing chokepoint for every next-generation SMR and microreactor regardless of which reactor design wins -- making it picks-and-shovels for the entire domestic nuclear buildout.

Position

  • T3-tranche position in the nuclear processing layer; established May 2026 and scaled later that month. STCG profile through ~May 2027 (hold-only window).
  • Entry-add band refreshed 2026-06-10; band details are withheld while a staged accumulation plan is active.

Thesis (detailed)

Centrus holds the only US license to produce HALEU -- high-assay low-enriched uranium (enriched to 5-20% U-235), the fuel required by most next-generation reactor and microreactor designs. This is not a competitive moat that could be replicated quickly: the HALEU demonstration cascade at the American Centrifuge Plant in Piketon, Ohio took years to license under NRC special authorization, and no other domestic entity has cleared the regulatory path to HALEU production at scale.

The structural logic is straightforward. Mike already owns the mining layer (UUUU, URG, DNN). Those miners extract natural uranium -- but natural uranium at ~0.7% U-235 cannot power an advanced reactor. It must be enriched. HALEU is the enrichment grade that unlocks the SMR thesis. Without domestic HALEU supply, every US SMR program depends on foreign enrichment (historically Russia's TENEX, now being eliminated by the Prohibiting Russian Uranium Imports Act signed 2024). The cut runs both ways: Centrus itself sources more than half of its LEU-segment deliveries through 2027 from TENEX under DOE waivers, so the same policy wall that protects the HALEU moat is a supply risk to the legacy trading business (see Risks). LEU is the bridge from domestic mining to domestic deployment.

The DOE relationship is now a dated dependency, not a de-risker (revised 2026-06-10; the original "de-risks near-term revenue" framing did not survive the Q1 2026 10-Q). The HALEU Operation Contract funds cascade operation only through June 30, 2026 (Option 1a, funded $108.2M), and the FY2027 DOE budget proposal does not include funding for continued operation of the cascade; Option 1b requires a revised cost proposal before DOE will consider exercising it. The $900M HALEU Production Contract task order (selected January 5, 2026, with options up to an additional $170M) remains subject to negotiation of a definitive agreement, and Centrus lost the parallel $900M LEU Production task order to another bidder. Centrus is still revenue-generating -- not pre-revenue -- with FY2025 revenue of $448.7M and FY2026 guidance raised to $450-500M, which distinguishes it from every other nuclear watchlist name except BWXT. But the raised guidance itself assumes the $900M task order is finalized and funded. Monopoly license + picks-and-shovels positioning still hold; the government-revenue leg now carries two dated execution risks (see Risks and Triggers).

Analyst consensus at the 2026-05-14 writeup was Strong Buy with a 1Y target of $278 (vs. $213 writeup price). That snapshot predates the Q1 print and the June drawdown (~$148 on 2026-06-10) and needs re-verification before it carries weight in any decision. The thesis here is structural conviction and supply chain completion, not a 10x bet.

Recent catalysts (60-day rolling)

  • 2026-05-05/06: Q1 2026 print (8-K + 10-Q). Revenue $76.7M (+5% YoY); GAAP net income $10.0M (-63% YoY) driven by $18.9M advanced technology costs (pre-capitalization expansion spend) and a lapped one-time debt-extinguishment gain; adjusted net income $23.5M. FY2026 revenue guidance RAISED to $450-500M -- explicitly assuming the $900M DOE task order finalizes. Backlog $3.9B (of which $2.4B contingent on new capacity). Disclosed: FY2027 DOE budget proposal excludes HALEU cascade funding (Option 1a funded only through June 30, 2026).
  • 2026-04: Geiger Brothers selected as Piketon construction contractor (time-and-materials, performance period through January 2031; prior site experience on the existing HALEU cascade and the 2013 demonstration cascade).
  • 2026-03: Palantir manufacturing-optimization partnership (~$300M potential cost savings identified, early-stage figure); Oklo joint-venture exploration for HALEU deconversion services co-located at Piketon.
  • 2026-02-09: Fluor Federal Services EPC contract signed for the Piketon expansion (time-and-materials; cancellation fee $24M declining $2M/month).
  • 2026-05-13: T3 layer established -- first-ever T3 tranche position. Nuclear processing layer now operational in the portfolio.
  • 2026-05-22: T3 scaling add.
  • Upcoming dated: June 30, 2026 (HALEU cascade funding boundary); $900M task-order definitization (no announced date); Q2 2026 earnings August 4, 2026.

Note: LEU has limited public news cadence outside earnings and DOE contract milestones. Absence of headlines is normal, not bearish.

Risks / What would break the thesis

  • DATED: June 30, 2026 HALEU cascade funding boundary -- HOC Option 1a ($108.2M) is the only contracted government revenue for cascade operations and expires this date; the FY2027 DOE budget proposal excludes cascade funding. The "appropriations risk" flagged at writeup is no longer hypothetical -- it has a date.
  • DATED: $900M HALEU Production task order fails to definitize -- raised FY2026 guidance assumes finalization and funding; formal collapse breaks the government-co-investment leg of the expansion thesis.
  • TENEX supply dependency -- more than one-half of LEU expected to be delivered to customers through 2027 is sourced from TENEX (Rosatom) under DOE waivers (third waiver application still pending) and per-shipment Russian export licenses with no certainty of future issuance; January 2025 Treasury sanctions already forced a payment-delay arrangement. The Russian ban is a moat for HALEU and a supply risk for the LEU trading segment at the same time.
  • Dilution -- share count grew 18.1% in FY2025 via ATM; convertible notes ($1,207.5M face, 2.25% tranche convertible at ~$97.50) add up to ~12.4M shares on conversion; a $1.0B shelf (effective November 2025) sits unused. An equity raise that funds operations rather than capacity = invalidation.
  • Uranium price collapse removes urgency for domestic fuel supply investment and pressures all upstream names including LEU
  • Competitor HALEU license approved -- if another US entity (e.g., Urenco USA, BWXT advanced enrichment) clears NRC HALEU authorization, the monopoly thesis is diluted (timeline: years, not imminent, but the structural moat is regulatory not technological)
  • Expansion execution -- the multi-billion-dollar Piketon buildout is explicitly contingent on "securing substantial public and private investment"; $2.4B of the $3.1B LEU backlog is contingent on capacity that does not exist yet; first Oak Ridge centrifuges come online in Ohio in 2029

Triggers

Entry trigger: SATISFIED 2026-05-13. Position established.

Scaling triggers (refreshed 2026-06-10): The entry-add band was refreshed 2026-06-10; band details are withheld while a staged accumulation plan is active. Non-space sector, so the position sits outside the space-cluster sector cap.

Dated watch-items (both inside the current window): 1. June 30, 2026 -- HALEU cascade funding boundary. Option 1a is funded ($108.2M) only through this date; the FY2027 DOE budget proposal excludes cascade funding; Option 1b needs a revised cost proposal before DOE will consider it. Non-resolution or a negative headline is gap-down risk; resolution is a thesis confirmation. 2. $900M HALEU Production task order definitization. Selected January 5, 2026; no definitive agreement as of the Q1 10-Q; raised FY2026 guidance assumes it closes; Centrus lost the parallel $900M LEU Production order. Definitization = confirmation; formal collapse = thesis-break event.

Do not trim: STCG-locked until ~May 2027. Also a structural conviction hold — the thesis is supply-chain completion, not a momentum trade.

Watch items post-entry: - HALEU cascade funding boundary headlines (June 30, 2026) and $900M task-order definitization -- see Dated watch-items above - Shares outstanding trend (dilution signal; $1.0B shelf effective November 2025, unused as of the Q1 10-Q) - Any new HALEU license application by competitor (monitor NRC ADAMS docket) - Q2 2026 earnings print: August 4, 2026 (verified 2026-06-10)

External authoritative sources

Open questions / hypotheses

  1. ANSWERED 2026-06-10: Q2 2026 earnings date is August 4, 2026 (verified; beta 1.44 remains below the >3 threshold).
  2. ANSWERED 2026-05 (Q1 10-Q): the cascade is operating under HOC Option 1a, funded $108.2M through June 30, 2026; HALEU Operation Contract revenue rose $9.8M YoY in Q1. Open residue: Phase 2 costs incurred after November 2024 remain undefinitized (no fee recorded) -- watch for definitization.
  3. PARTIALLY ANSWERED: the Piketon expansion targets at least 12 metric tons/year of HALEU capacity (Geiger 8-K). Still open: current demonstration-cascade production rate (only the cumulative 900 kg Phase 2 figure is disclosed) and the capacity gap vs. projected SMR demand through 2030.
  4. Is Urenco USA or any other entity in active NRC pre-application for HALEU authorization? If yes, moat timeline shortens. (Still open; monitor ADAMS docket.)
  5. NEW: Does Congress restore HALEU cascade funding for FY2027 (appropriation, supplemental, or new task order) before/after the June 30, 2026 boundary?
  6. NEW: When does the $900M HALEU Production task order definitize, and on what terms? Guidance realization depends on it.
  7. NEW: Refresh the analyst consensus (the $278 / Strong Buy figure is a 2026-05-14 snapshot; price has since traded ~$148).

Decision log

  • 2026-05-12: Page created.
  • 2026-05-13: T3 layer established -- first-ever T3 tranche.
  • 2026-05-14: Page moved from watchlist/ to stocks/. Status: watchlist → hold. Reflects held-position state.
  • 2026-06-10: Wiki refreshed against the Q1 2026 filing arc (FY2025 10-K through Q1 10-Q; thesis state 2026-05-18). "DOE relationship de-risks near-term revenue" retired as a thesis line -- replaced by two dated execution risks (June 30, 2026 HALEU cascade funding boundary; $900M HALEU Production task-order definitization). Entry-add band refreshed and fenced private while the staged accumulation plan is active.